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BACKGROUND: An accurate and simple risk prediction model that would facilitate earlier detection of pancreatic adenocarcinoma
(PDAC) is not available at present. In this study, we compare different algorithms of risk prediction in order to select the best one for
constructing a biomarker-based risk score, PancRISK.
METHODS: Three hundred and seventy-nine patients with available measurements of three urine biomarkers, (LYVE1, REG1B and
TFF1) using retrospectively collected samples, as well as creatinine and age, were randomly split into training and validation sets,
following stratiﬁcation into cases (PDAC) and controls (healthy patients). Several machine learning algorithms were used, and their
performance characteristics were compared. The latter included AUC (area under ROC curve) and sensitivity at clinically relevant
speciﬁcity.
RESULTS: None of the algorithms signiﬁcantly outperformed all others. A logistic regression model, the easiest to interpret, was
incorporated into a PancRISK score and subsequently evaluated on the whole data set. The PancRISK performance could be even
further improved when CA19-9, commonly used PDAC biomarker, is added to the model.
CONCLUSION: PancRISK score enables easy interpretation of the biomarker panel data and is currently being tested to conﬁrm that
it can be used for stratiﬁcation of patients at risk of developing pancreatic cancer completely non-invasively, using urine samples.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0694-0
BACKGROUND
Since the Framingham study in 1976, yielding a ﬁrst risk prediction
model for coronary heart disease, a number of prediction models
have been reported for various medical conditions, including
cancer.1–5 In pancreatic ductal adenocarcinoma (PDAC), few such
models have been designed, including the ones for absolute risk
prediction6–12 and gene carrier status prediction,13 as well as
prediction models in groups at risk.14,15 Recently, two independent
models to determine the risk of PDAC in patients in new-onset
diabetes (NOD) cohort have also been reported.16,17 Most of these
prediction models are based on previously established risk factors,
relevant laboratory ﬁndings and clinical symptoms, but none have
as yet been thoroughly validated or adopted in the clinic.
We have recently reported on three-biomarker panel in urine
with promising characteristics for early detection of PDAC.18
In order to enable its utilisation and allow for seamless result
interpretation in the clinical setting, we aimed to develop a risk
score based on these three biomarkers, age and urine creatinine.
In order to ascertain whether the most appropriate and best
performing model is utilised, we have compared several different
algorithms: neural network (NN), random forest (RF), support
vector machine (SVM), neuro-fuzzy (NF) technology, and logistic
regression model. These are all supervised methods that require a
training set of patients with known case/control labels. Following
the training stage, all these methods could be applied to new
patients, which would give the risk of the disease or the exact
prognosis of the class (case/control) label.
Each of these methods has its advantages and disadvantages.
The most widely used approach in clinical studies is multivariable
regression, with logistic regression being the most appropriate
for the binary outcome (case/control).19 It includes continuous,
categorical and ordinal variables and does not require a normal
distribution of the predictors while providing coefﬁcients that can
be easily converted into odds ratios (ORs) with straightforward
interpretation. Another method, Deep Learning, has also been
widely applied to different biomedical data sets.20,21 Although
deep NNs are more suitable for large data sets, they have also
been successfully utilised for a small volume medical data.22
RF is another common machine learning technique utilised for
building the predictive models. It is an ensemble learning method
for classiﬁcation based on the Condorcet’s jury theorem stating
that a set of competent, independent jurors that are making a
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decision on a binary outcome using the majority voting scheme
will be more effective with the increasing number of jurors. One of
the main advantages of this approach is that combining multiple
decision trees avoids overﬁtting.23–25 Similarly, SVM is a supervised
learning algorithm that transforms the original input space into a
higher-dimensional feature space to ﬁnd the hyperplane that
separates the classes in an optimal way. The “penalty” term that
controls the trade-off between margin and training errors
prevents the overﬁtting of the model.26
A more recent technique, NF technology, models complex
processes and solves the optimal set partitioning problems in case
of uncertainty.27,28 This approach unites two independent mathe-
matical constructions, fuzzy logic29 and NNs, which offers the
possibility to combine the ability of NNs to learn with transparency
and easy interpretation of fuzzy rules “If–Then”.30,31
All ﬁve algorithms were tested; they were ﬁrst trained on a
subset of data and subsequently validated using the remaining
subset.
MATERIALS AND METHODS
Clinical sample set for the analysis
The data utilised for this analysis was obtained by enzyme-linked
immunosorbent assays for the three biomarkers on the specimens
collected at the Royal London Hospital, University College London
Hospital, Department of Surgery, Liverpool University and the
CNIO Madrid, Spain, combined with creatinine and patient’s age
as described in ref. 18 In addition to the already available data,
further samples obtained from Pancreas Tissue Bank (https://www.
bartspancreastissuebank.org.uk) were also analysed in the same
fashion, deriving a total set of 180 healthy controls and 199 PDAC
samples (102 stage I/II and 97 stage III/IV) (these data will be
reported in more detail separately). The analysis was performed
with Ethical approval given by North East-York Research Ethics
Committee (Ref: 18/NE/0070).
Training of algorithms
Logistic regression, NN, RF, SVM and NF technology were trained
in the training set and tested in the validation set after random
division in a 1:1 ratio. The training set included both PDAC and
healthy patients.
A logistic regression model was ﬁtted for the training set using
the ﬁve predictors—three urine biomarkers together with
creatinine and age. Bootstrap cross-validation was used for the
internal validation to ensure that the overﬁtting is avoided.32
Following that, elastic net was used for the regularisation of the
coefﬁcients to obtain the ﬁnal model.33 The “glmnet” package
from R was used to implement the logistic regression model with
elastic net regularisation.
The depth and architecture of NNs was varied in our study. In
particular, NNs with 1–16 hidden layers with increasing number
of neurons from 16 neurons in the ﬁrst layer to 256 neurons in
the last layer were tried. Also, different optimisers, learning rates
and activation functions were attempted. As a result, the
optimal model was found empirically and consisted of 7 feed-
forward hidden layers with 32, 32, 64, 64, 128, 128 and 2
neurons, respectively, and 6 dropout layers with probability
equal to 0.2 in between the hidden layers. The NN was trained
on standardised features. Finally, the NN was trained for 100
epochs with batch size of 16 using the Adam optimiser with
learning rate of 0.001. To implement the model and test its
performance, the following Python packages were used: tensor-
ﬂow, keras, and scikit-learn.34
The RF of conditional inference trees was ﬁtted on the training
set. The “party” package from R was used and then applied to the
validation set to test its performance. Such implementation
provided ﬁxed values for sensitivity and speciﬁcity in the
validation set rather than a range of values, therefore the area
under the Receiver Operating Characteristic (ROC) curve (AUC)
was not calculated for this approach.
To select optimal parameters of SVM,35 a ten-fold cross
validation was used. The “svmLinear” method from the “caret”
package in R was used to train and test the SVM.
For tuning of the NF method, the r-algorithm developed by
Shor was used with a precision ε= 0.001.36 Software implementa-
tion of this approach was developed within the Visual Studio 2013
environment.
Statistical analysis
The outcome of the analysis was PDAC diagnosis.
The null hypothesis in this study was that the logistic regression
model, the easiest to implement and evaluate from the list of
algorithms, performs no worse than any of the more sophisticated
techniques.
The performance characteristics of the algorithms were evaluated
and compared in terms of the sensitivity (SN; proportion detected of
those with cancer) at a ﬁxed speciﬁcity (SP; proportion of healthy
controls correctly detected not to have cancer); for RF and SVM, the
threshold was implicit in its formulation; for logistic regression, NN
and NF technology, the threshold was the value that provided an SP
of 0.90; and the AUC. Inference for the ROC curves was based on
cluster-robust standard errors that accounted for the serially
correlated nature of the samples. It was not possible to create ROC
curves and therefore AUC for RF and SVM since the outcome was not
continuous. McNemar’s exact test was used to assess the signiﬁcance
of difference in SN at ﬁxed SP and DeLong’s test was used to assess
the signiﬁcance of differences in AUC between approaches.37
Conﬁdence intervals (CI 95%) for AUCs were derived based on the
DeLong’s method to evaluate the uncertainty of an AUC; SN and SP
95% CI were derived using bootstrap replicates.
To allow for multiple testing, both types of tests were adjusted
using the Bonferroni correction. Since the primary hypothesis
pertained to the logistic regression model, all other approaches
were compared to this model, and a threshold of 0.05/4= 0.0125
was used to deﬁne a signiﬁcant result after adjustment for
multiplicity.
All analyses were performed in R version 3.5.1 and Python
version 3.0.
Table 1. Details of cases and controls in the training and validation sets.
Age Creatinine (g/L) LYVE1 (ng/mL) REG1B (ng/mL) TFF1 (ng/mL)
Healthy samples Training set (n= 95): mean (sd) 56.495 (12.095) 0.73 (0.543) 1.196 (1.994) 43.271 (72.339) 135.779 (224.582)
Testing set (n= 85): mean (sd) 56.518 (12.121) 0.851 (0.574) 1.231 (1.871) 38.855 (49.385) 193.749 (325.936)
p value 0.999 0.107 0.444 0.616 0.11
PDAC samples Training set (n= 96): mean (sd) 66.271 (9.934) 0.94 (0.678) 5.542 (3.662) 216.731 (262.845) 1124.184 (1158.383)
Testing set (n= 103): mean (sd) 66.097 (11.066) 0.894 (0.767) 6.019 (3.891) 235.235 (290.935) 1171.382 (1641.401)
p value 0.979 0.244 0.395 0.674 0.773
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In total, 379 samples were included in the analysis. The training
and validation sets comprised of 191 patients (96 PDAC cases and
95 controls) and 188 patients (103 PDAC and 85 controls),
respectively. Characteristics of samples were balanced (Table 1).
Following the training stage, all the algorithms were applied to the
validation set. Figure 1 shows the ROC curves for the logistic
regression, NN and NF technology for detection of PDAC cases.
Circle points on the ROC curves give particular values of SN and SP
provided by SVM and RF. Logistic regression and NF technology
provided the same AUC, 0.94 (95% CI: 0.91–0.97), slightly higher
than the ﬁgure of 0.93 (95% CI: 0.9–0.97) for the NN; however, the
difference was not signiﬁcant (p= 0.26 for logistic regression vs
NN and p= 0.24 for NF technology vs NN). At a ﬁxed SP of 0.9, SN
was 0.81 (95% CI: 0.7–0.89) for logistic regression, 0.81 (95% CI:
0.63–0.95) for NN and 0.87 (95% CI: 0.72–0.95) for NF technology
(Table 2). Since the outcome of the SVM and RF algorithms was
not continuous, these are included with actual speciﬁcities that
they provided.
To assess the signiﬁcance of differences in sensitivity at ﬁxed
speciﬁcity for different algorithms, McNemar’s exact test was used
and adjusted for the multiple comparison of four algorithms with
the logistic regression. As seen in Table 2, none of the approaches
signiﬁcantly outperformed logistic regression implying that the
null hypothesis cannot be rejected. In a subgroup analysis of early
and late PDAC stage (Table 3), performance was similar with
differences in AUC between the logistic regression and other
techniques being negligible. Therefore, logistic regression was
implemented into a PancRISK using all the available data.
To analyse whether CA19-9, a commonly used pancreatic
cancer biomarker, is complementary to the developed PancRISK,
both were evaluated in the subset of data where plasma CA19-9
measurements were available. Samples were classiﬁed by the
PancRISK as “Normal” or “Abnormal” based on the threshold that
provided the speciﬁcity of 0.9 while for CA19-9 the clinically used
cut-off of 37 U/mL was used. Table 4 shows the number of healthy
and PDAC samples that were classiﬁed as “Normal” and
“Abnormal” using the PancRISK and CA19-9 37 U/mL cut-off. The
rule of “Either PancRISK or CA19-9 is Abnormal” provided
speciﬁcity of 87/91= 0.96 and sensitivity of 144/150= 0.96.
DISCUSSION
With increased incidence and no major improvements in
detection and therapeutic approaches, PDAC stubbornly remains
one of the few cancers with exceptionally poor prognosis. We
believe that earlier cancer detection, when still in fully resectable
stage, using a non-invasive testing will likely be critical in
improving the currently bleak outcome for pancreatic cancer
patients. Owing to fairly small incremental increase in overall risk
even when several well-known risk factors are combined, with or
without adding PDAC symptoms (due to their late occurrence
and non-speciﬁc nature), prediction risk models based on
molecular biomarkers are more likely to accelerate earlier
detection of PDAC.
In this study, in order to assemble a biomarker-based risk score,
we have used our urinary biomarker data to compare ﬁve different
classiﬁcation techniques: logistic regression, NN, RF, SVM, and NF
technology, and found that all of them had performed similarly
and therefore the null hypothesis about their equality cannot be
rejected. Since the logistic regression was not outperformed by
any of the more sophisticated approaches, it was implemented in
the construction of PancRISK score. This choice is substantiated by
the fact that, out of all the utilised algorithms, it is the most
straightforward to implement and interpret.
The performance of PancRISK was subsequently compared
toplasma CA19-9 in a subset of data where matched measure-
ments were available. The comparison indicated that this
combination could provide very high sensitivity and speciﬁcity
of PDAC detection.
The intended use of PancRISK is in stratiﬁcation of patients to
the ones with normal (“Normal”) or elevated (“Abnormal”) risk,
with further, more expensive and invasive clinical workup being
indicated in the latter group. The PancRISK could thus be utilised
in the surveillance of individuals with familial history and genetic
background or in patients with increased risk due to inﬂammatory
diseases of pancreas, such as chronic pancreatitis. Furthermore,
it would also be interesting to assess the model in the PC-NOD
group with intermediate ENDPAC score.17
Our study has several limitations, the main one being that,
while we aim to detect cancer at an earliest possible stage, about
half of PDAC cases in our data set were late-stage patients. This is
due to challenges in ﬁnding PDAC patients with early-stage
disease, as most are currently diagnosed when the disease is
either locally advanced or already metastatic. Similarly, we
have used healthy people as a proxy for individuals with genetic
background until such samples become available to us.
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Fig. 1 Performance characteristics of urine biomarkers inter-
preted using logistic regression, neural network, neuro-fuzzy
technology, random forest and support vector machine for
detection of pancreatic cancer (PDAC) cases. Circle points give
particular values of sensitivity and speciﬁcity provided by random
forest and support vector machine. LR logistic regression, NN neural
network, NFT neuro-fuzzy technology, RF random forest, SVM
support vector machine, AUC area under ROC curve.
Table 2. Cut-point sensitivity, speciﬁcity, area under curve (AUC).
Method Logistic regression Neural network Neuro-fuzzy technology SVM Random forest
Speciﬁcity 0.9 0.9 0.9 0.89 0.82
Sensitivity (95% CI) 0.81 (0.7–0.89) 0.81 (0.63–0.95) 0.87 (0.72–0.95) 0.82 0.86
p value 1 0.077 1 0.18
AUC (95% CI) 0.94 (0.91–0.97) 0.93 (0.9–0.97) 0.94 (0.91–0.97)
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combination with CA19-9, where both measurements were
available only in a subset of patients. The main strength of
our study, however, is the comprehensive comparison of ﬁve
different classiﬁcation algorithms, which was our main goal. As
there are only ﬁve predictors used in building our predictive
models, the ten events per variable rule of thumb is easily
satisﬁed.38 Thus the volume of data analysed here enabled us to
conclude that the logistic regression is the appropriate model for
building the prediction of PDAC risk.
The performance of PancRISK now requires further evaluation in
the large number of prospectively collected specimens in a setting
of a clinical observational study, both alone and in the
combination with CA19-9, which will give a deﬁnitive estimate
of the predictive power of such a combination.
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